About Ubiquitin recognition factor in ER-associated degradation protein 1
Ubiquitin recognition factor in ER-associated degradation protein 1 (UFD1) is a protein
from Homo sapiens identified by UniProt accession
Q92890, 307 residues long.
MolForge cross-references it against 0 known binders and
37 disease associations.
Target properties
| Protein name | Ubiquitin recognition factor in ER-associated degradation protein 1 |
|---|
| UniProt accession | Q92890 |
|---|
| Gene | UFD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 307 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (37)
Diseases linked to this target (Open Targets).
- infect · score 0.08
- infection · score 0.08
- acute lymphoblastic leukemia · score 0.08
- neoplasm · score 0.05
- Stroke · score 0.04
- mean platelet volume · score 0.03
- brain measurement · score 0.03
- schizophrenia · score 0.03
- blood protein measurement · score 0.02
- viral disease · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92890-F1 | alphafold | PREDICTED | 74.60 | — |
Amino-acid sequence (307 residues)
MFSFNMFDHP IPRVFQNRFS TQYRCFSVSM LAGPNDRSDV EKGGKIIMPP SALDQLSRLN ITYPMLFKLT NKNSDRMTHC GVLEFVADEG ICYLPHWMMQ NLLLEEGGLV QVESVNLQVA TYSKFQPQSP DFLDITNPKA VLENALRNFA CLTTGDVIAI NYNEKIYELR VMETKPDKAV SIIECDMNVD FDAPLGYKEP ERQVQHEEST EGEADHSGYA GELGFRAFSG SGNRLDGKKK GVEPSPSPIK PGDIKRGIPN YEFKLGKITF IRNSRPLVKK VEEDEAGGRF VAFSGEGQSL RKKGRKP
Explore Ubiquitin recognition factor in ER-associated degradation protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets